SunAct Cancer Institute Pioneers Life-Saving Treatment for Deadly Brain Tumor
Newz Daddy Healthcare Updates
Synopsis of the Article
- Breakthrough in Brain Cancer Treatment: SunAct Cancer Institute becomes the first in India to offer CAR-T therapy for Midline Glioma.
- Targeting a Deadly Disease: Midline Glioma primarily affects children and young patients, with historically poor survival rates.
- A New Era in Neuro-Oncology: CAR-T therapy offers renewed hope by using a patient’s immune system to fight this aggressive cancer.
- Expert Statement: Dr. Vijay Patil, Founder of SunAct Cancer Institute, highlights the potential of CAR-T therapy to transform survival outcomes.
- Current Treatments and Limitations: Standard treatments like radiation and chemotherapy have limited success, with median survival rates of under a year.
- Promise of GD-2 CAR-T Therapy: First highlighted in Nature in 2016, GD-2 CAR-T therapy is a promising step towards precision medicine.
- Expanding Cancer Innovations at SunAct: The institute has previously introduced Allogenic CAR-T for solid tumors and Bi-Specific CAR-T for multiple myeloma.
- International Collaborations: SunAct has partnerships with Abgentil and CytoMed for further advancements in CAR-T and TIL therapies.
- Potential to Redefine Survival Rates: Ongoing research and clinical trials could establish CAR-T therapy as a new standard for treating Midline Glioma.
- More Information: SunAct Cancer Institute’s official website: SunAct Cancer Institute
For young patients suffering from one of the most deadly types of brain cancer, a significant advancement in cancer treatment has been made in India. For the first time in the nation, SunAct Cancer Institute is providing CAR-T therapy for midline glioma, a condition that has historically had a very low survival rate.
With few treatment choices and a median survival duration of less than a year, children and young adults with Midline Glioma have long faced devastating odds. However, with the introduction of CAR-T therapy, a cutting-edge approach that empowers the body’s immune system to fight cancer, the future looks far more promising.
“We believe this marks the beginning of a new era in neuro-oncology, where we can finally harness the power of a patient’s immune system to target what was once considered an untreatable disease,” said Dr. Vijay Patil, founder of SunAct Cancer Institute, who expressed his excitement about this milestone.
One of the most dangerous forms of brain tumors, midline gliomas primarily affect children and young people. It occurs in regions that are very challenging to operate on, such as the thalamus, spinal cord, or brainstem. Standard treatments, such as biopsy, radiation therapy, temozolomide chemotherapy, and ONC-201 therapy, have shown limited success, leaving families with few options and little hope.
The biggest challenge with Midline Glioma is its resistance to conventional therapies, which makes finding alternative treatments a top priority in pediatric oncology.
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a revolutionary cancer treatment that modifies a patient’s immune cells to recognize and destroy cancer cells. It has been highly successful in blood cancers and is now showing great potential for solid tumors like Midline Glioma.
One of the most promising approaches is GD-2 CAR-T therapy, which was first highlighted in the journal Nature in November 2016. This therapy specifically targets the GD-2 protein, commonly found on Midline Glioma tumors, allowing for more precise and effective cancer treatment.
Unlike traditional treatments that merely slow down the disease, CAR-T therapy actively fights and eliminates tumor cells, potentially extending survival rates and even achieving remission in some cases.
SunAct Cancer Institute has consistently been at the forefront of groundbreaking cancer therapies. Some of its key achievements in CAR-T and cell-based therapies include:
July 20, 2024 – First to offer Allogenic CAR-T Cell therapy for solid tumors.
November 27, 2024 – First to introduce Bi-Specific CAR-T therapy for multiple myeloma (a type of blood cancer).
December 13, 2024 – Partnership with Abgentil to advance CAR-T Cell & Tumor-Infiltrating Lymphocyte (TIL) therapies.
January 7, 2025 – Collaboration with CytoMed for Phase 2 clinical trials on Gamma Delta CAR-T therapy, marking one of the biggest technological innovations in Asia.
While CAR-T therapy is still in its early stages for Midline Glioma, research and clinical trials suggest it could significantly improve survival rates and eventually become a standard treatment. Experts believe that with continued advancements, the success seen in blood cancers could soon be replicated in aggressive brain tumors.
Families dealing with a Midline Glioma diagnosis now have a reason to hope. SunAct Cancer Institute’s initiative could be a game-changer for pediatric oncology, ensuring that more children and young patients have a fighting chance against this deadly disease.
Must Read:
Meril’s Robotic Innovation Summit Sets a New Benchmark for Surgery in India
“Quick Action Can Save Lives: Marengo CIMS’s Game-Changing Emergency Care Program”